Sample validation for F1CDx companion diagnostic claims.

NIAID Data Ecosystem2026-03-13 收录

伴随诊断

基因组检测

数据链接：

https://figshare.com/articles/dataset/Sample_validation_for_F1CDx_companion_diagnostic_claims_/19371052 数据链接链接失效反馈

官方服务：

资源简介：

Sample validation for F1CDx companion diagnostic claims.

创建时间：

2022-03-16

Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma

肿瘤免疫治疗预后预测

伴随诊断

While immune checkpoint inhibitor (ICI) therapies can significantly improve outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC), only about 15–20% benefit

NIAID Data Ecosystem70

Companion Diagnostics Market

伴随诊断

市场分析

Companion Diagnostics is projected to register a 10.9% CAGR from 2024 to 2030, driven by North America, Europe, Asia Pacific, Latin America, Middle East, and Africa markets

www.usdanalytics.com60

North America Companion Diagnostic Tests Market

伴随诊断

市场预测

North America Companion Diagnostic Tests comes with extensive industry analysis of development components, patterns, flows, and sizes. The report calculates present and past market values to forecast

IMR REPORTS40

Comparative analyses of IHC-based and molecular-based EGFR mutational status.

EGFR基因突变检测

伴随诊断

*:The cases with both E19 (E746–A750) and E21 (L858R) mutations were not counted twice.Other mutations:L747–P753insS deletion mutation in exon 19 and L861Q point mutation in exon 21.

Figshare2015-12-02 更新60

A Multiple Reaction Monitoring (MRM) Method to Detect Bcr-Abl Kinase Activity in CML Using a Peptide Biosensor

白血病研究

伴随诊断

The protein kinase Bcr-Abl plays a major role in the pathogenesis of chronic myelogenous leukemia (CML), and is the target of the breakthrough drug imatinib (Gleevec™). While most patients respond wel

Figshare2016-01-18 更新40

Sample validation for F1CDx companion diagnostic claims.

资源简介：

相关数据集